Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: Randomized phase II study

H. S. Han, V. Diéras, M. Robson, M. Palácová, P. K. Marcom, A. Jager, I. Bondarenko, D. Citrin, M. Campone, M. L. Telli, S. M. Domchek, M. Friedlander, B. Kaufman, J. E. Garber, Y. Shparyk, E. Chmielowska, E. H. Jakobsen, V. Kaklamani, W. Gradishar, C. K. RatajczakC. Nickner, Q. Qin, J. Qian, S. P. Shepherd, S. J. Isakoff, S. Puhalla*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

160 Scopus citations

Fingerprint

Dive into the research topics of 'Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: Randomized phase II study'. Together they form a unique fingerprint.

INIS

Pharmacology, Toxicology and Pharmaceutical Science